Cereno Scientific AB Logo

Cereno Scientific AB

Clinical-stage biotech developing drugs for rare cardiovascular & pulmonary diseases.

CRNO | ST

Overview

Corporate Details

ISIN(s):
SE0008241541 (+3 more)
LEI:
549300VX8KTMYDS6NM84
Country:
Sweden
Address:
BioVentureHub, 431 83 Mölndal

Description

Cereno Scientific is a clinical-stage biotechnology company developing disease-modifying therapeutics for rare cardiovascular and pulmonary diseases. The company's pipeline focuses on epigenetic modulation and includes a portfolio of Histone Deacetylase (HDAC) inhibitors in clinical development. These candidates are designed to address the root mechanisms of complex diseases. In the preclinical stage, the company is advancing assets such as CS585, a novel prostacyclin (IP) receptor agonist. The strategic focus on rare diseases targets underserved patient populations with significant unmet medical needs, aiming to provide high treatment value and potentially enable shorter development timelines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cereno Scientific AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cereno Scientific AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cereno Scientific AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-16 Sten Sörensen Other Other 866,665 86,666.50 SEK
2024-11-25 Security Holding Sverige AB Other Buy 20,000 99,800.00 SEK

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.